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Abstract 
Purpose: To evaluate the physical characteristics (size, legibility or readability) and the completeness 
of information in drug package leaflets/inserts and drug promotional brochures in Nigeria.  
Methods: Three hundred materials (drug information leaflets and brochures) were collected from 
various community pharmacies, private and governmental clinics and from various pharmaceutical 
distributor or representatives from different states of Nigeria. Two independent panels sorted and 
evaluated the information found in them and differences were resolved by consensus.  
Results: This study revealed that 80.7 % of the materials evaluated were leaflets while brochures 
accounted for 18 %. The physical characteristics of the materials showed that 58.7, 31.3 and 89.0 % of 
the materials were sizeable, readable/legible and had adequate color contrast respectively. Most of the 
materials were written in English (78.7 %), English and French 17.3 %, English and Arabic accounted 
for only 4 %. Description of indications for which the drugs were used was mentioned in 30.3 % of 
materials. Other contents of the materials were mechanism of action (70.3 %), overdoses information 
(55.0 %), drug interaction (51.3 %), pharmacokinetics (36.3 %) and revision date of the information 
(21.0 %). 
Conclusion: This study reveals that advertising materials used in promoting drugs in Nigeria have 
incomplete information and the physical characteristics of the materials are not adequate. It seems that 
drug industries at present mainly aim at increasing sales rather than promoting health care. Information 
in some pharmaceutical brochures exaggerated the benefits of the drug and downplayed risks 
associated with the drugs.  
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Drug promotion, according to World Health 
Organization (WHO), refers to all the 
informational and persuasive activities of the 
pharmaceutical industries, the effect of which is 
to induce prescription, supply, purchase, and use 
of medicinal drugs [1]. Such persuasive activities 
includes the activities of medical representatives, 
direct-to-physician promotion (DTPP), provision 
of gifts and drug samples, drug package inserts, 
direct-to-consumer advertisements (DTCA), 
periodicals, telemarketing, holding of 
conferences, symposium and scientific meetings, 
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sponsoring of medical education, advertisements 
through radio, TV,  pamphlet and organizing 
promotional trials [2].  
 
In recent times however, WHO and some NGOs 
are becoming worried about the unethical and 
inappropriate approach to the promotion of 
drugs, devices and other pharmaceutical 
products. As at 1997, in a seminar on WHO’s 
Ethical Criteria for Medicinal Drug Promotion, 
there was a firm agreement that inappropriate 
promotion of medicinal drugs is still a problem 
both in developing and developed countries [3]. 
Promotional materials, according to WHO’s 
Ethical Criteria for Medicinal drug Promotion, 
should include the name of the active ingredient, 
brand name, content of active ingredient per 
dosage form or regimen, other ingredients known 
to cause problems, approved therapeutic uses, 
dosage form or regimen, side effects, 
contraindications, major interactions, 
management in case of overdose or toxicity, 
storage conditions, pharmacokinetic profile, use 
in pregnancy and lactation, name and address of 
manufacturers or distributor, and reference to 
scientific literature. Such information is believed 
to increase public’s awareness of diseases and 
other health conditions. This will help people to 
take responsibility for their own health by 
teaching them how to recognize disease, and 
motivate them to seek medical attention for 
condition that might, otherwise be left 
undiagnosed and untreated. Unfortunately, many 
drug promotional materials do not meet this 
standard. This research work is therefore aimed 
at evaluating the information in drug promotional 






This was a descriptive study based on critical 
appraisal of drug promotional brochures and 
leaflets. Three hundred materials (drug package 
leaflet = 242 and promotional brochures = 58) 
were collected from community pharmacies, 
private and governmental clinics and various 
pharmaceutical companies in different states of 
Nigeria. These leaflets and brochures were 
sorted to avoid selecting more than one 
particular material. All the drug information 
materials for promotion of prescription and non-
prescription drugs available and within the reach 
of the researchers at the time of this study were 
collected and evaluated. Evaluated materials 
included 242 leaflets, and 58 brochures issued 
by pharmaceutical companies. The whole 
materials were given an identification number for 
easy evaluation based on their therapeutic 
classes. 
 
Size, readability and color contrast test 
 
The size, the readability or legibility and color 
contrast of the information materials were 
evaluated. In Nigeria, there are no regulations 
concerning the readability of labeling and 
package inserts of medicinal products [4] and as 
a result, we hypothesized that a material was 
sizable if it was equal or greater than half of A4 
paper (about 8.27 × 5.80 inches); readable or 
legible if the font size is equal to or more than 10; 
good color contrast if the material had white 
background with black, blue, or green printing. 
The size, legibility, color contrast and drug 
information contained in these materials were 
evaluated by two independent panels (two 
pharmacists). The information examined 
comprises of the following: Name of condition 
treated with the promoted drug, Information 
about the condition, Symptoms associated with 
the condition, Conditions prevalence, 
Misconception about the condition, Risk factors 
associated with the condition, Information about 
the treatment, Drug generic name, Mechanism of 
action, Composition, Onset time, Dosage 
regimen, Duration of treatment, Adverse effects, 
Precautions, Drug-drug and drug-food 
interactions, Over dosage, Contraindication, 
Lifestyle or behavioral changes necessary, 
Available competing treatment, Storage condition 
and Date of revision.  
 
The information was assessed using current 
Nigerian drug Index (N.D.I) and British National 
Formulary (BNF) in line with WHO Ethical 
Criteria for Medicinal Drug Promotion [1], each of 
the panels evaluated the materials to determine 
the presence or absence of information about 
specific condition for which the drug was 
promoted and about the drug profile. After the 
evaluation, the two panels resolved differences 




Data analysis was carried out using SPSS 
version 16. The analysis was based on 
classification of content into the type of 
advertising materials and place of origin, i.e., 
difference in information of imported and locally 
produced. Drugs information studied were the 
same as those distributed in other states, thus 
the sample subjected to analysis is 
representative of the situation in the whole 
country. 
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This study revealed that 80.7 % of the materials 
evaluated were leaflets while brochures 
accounted for 18 %. The physical characteristics 
of the materials showed that 58.7, 31.3 and 89.0 
% of the materials were sizeable, 
readable/legible and had adequate color contrast 
respectively. Most of the materials were written in 
English (78.7 %), English and French 17.3 %, 
English and Arabic accounted for only 4 %. 
Description of indications for which the drugs 
were used was mentioned in 30.3 % of materials. 
Other contents of the materials were mechanism 
of action (70.3 %), overdoses information (55.0 
%), drug interaction (51.3 %), pharmacokinetics 
(36.3 %) and revision date of the information 
(21.0 %), as shown in Table 1. 
 
The type of incomplete information observed in 
the leaflet include lack of side effect 38 (15.7 %), 
contraindication 58 (23.9 %) overdose 
information 131 (54.1 %), storage condition 76 
(31.4 %), drug interactions 138 (57.0 %), 
precautions/cautions 51 (21.0 %), lifestyle 
changes 232 (95.8 %). Overall, information about 
treatment included in the promotional brochures 
scrutinized during the study period can be 
considered as unsatisfactory except for lifestyle 
modification 56 (96.5 %). 
 
The brochures and leaflets covered various 
therapeutic classes including cardiovascular, 
gastrointestinal, neurological, diabetes mellitus, 
infectious diseases, malaria, multivitamin and 
asthma medications. The drugs included 42 
brand names and 27 generics. These drugs 
covered Antibiotics, 23.7 %; Antimalaria, 9.3 %; 
Multivitamin, 13.3 %; Analgesics, 14.3 %; 
Antifungal 6.7 %; Antihypertensive, 3.3 %; Anti-
diabetes, 4 %; GIT drugs, 3.7 %; Gynecological 
drugs, 4.1 %; Antihistamine, 3.7 %; Anti-ulcer, 
3.3 %; Antitussive/expectorant, 2.0 %; 
Antiasthmatic, 3 %; Anticancer, 0.7 %; C.N.S 
drugs, 2.0 %; Antiepileptic, 0.3 % and 
Anthelmintics, 3.0 % cardiovascular drugs, 0.7 
%; Table 2. 
 
 
Table 1: Physical characteristics and therapeutic information of the promotion materials  
 
Information Promotional Materials Total (n=300) 
Leaflet (n=242) Brochure (n=58) 
Physical characteristics    
sizeable material 142 (58.7) 34 (58.6) 176 (58.7) 
Legibility or readable materials 76 (31.4) 18 (31) 94 (31.3) 
Adequate color Contrast 215 (88.8) 52 (89.6) 267 (89.0) 
Place of origin    
Local 41 (16.9) 2 (3.4) 43 (14.3) 
Imported 201 (83.1) 26 (96.6) 227 (85.7) 
Language    
English 178  (73.6) 58 (100.0) 236 (78.7) 
English and French 53 (21.9) 0 (0.0) 53 (17.7) 
English and others 11 (4.5) 0 (0.0) 11 (3.7) 
Target    
Physicians 5 (2.1) 58 (100.0) 63 (21.0) 
Consumers 237 (93.7) 0 (0.0) 237 (79.0) 
Drug name    
Brand 40 (16.5) 2 (3.4) 42 (13.7) 
Generic 25 (10.3) 2 (3.4) 27 (9.0) 
Both 177 (73.1) 54 (93.1) 231 (77.0) 
Therapeutic information    
Indications 220 (90.9) 58 (100) 278 (92.7) 
Mechanism of action 157 (64.9) 54 (93.1) 211 (70.3) 
Overdose information 111(46.1) 54 (93.1) 165 (55.0) 
Contraindications 184 (76.0) 53 (91.4) 237 (79.0) 
Compositions / ingredients 218 (90.1) 54 (93.1) 272 (90.7) 
Side effects / adverse effects 204 (84.3) 55 (94.8) 259 (86.3) 
Dosage regimen 232 (95.9) 56 (98.2) 288 (96.0) 
Precautions / cautions 191 (79.3) 54 (93.1) 245 (81.7) 
Drug interaction 104 (43.0) 50 (86.2) 154 (51.3) 
Storage condition 166 (68.9) 48 (82.8) 214 (71.3) 
Pharmacokinetics 59 (24.5) 50 (86.2) 109 (36.3) 
Lifestyle  10 (4.1) 2 (3.4) 12 (4.0) 
Date of last revision  22 (9.1) 41 (70.7) 63 (21.0) 
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Table 2: Classes of drugs whose promotion materials were mostly encountered  
 
Classes of drug  Leaflet (n=242) Brochure (n=58) Total 
Antibiotic 59  (24.4) 14 (24.1) 73 (23.7) 
Analgesic 35 (14.5) 10 (17.3) 45 (14.3) 
Multivitamin 39 (16.1) 2 (3.4) 41(13.3) 
Anti-malarial 25 (10.3) 4 (6.9) 29 (9.3) 
Antifungal 9 (3.7) 11 (19.0) 20 (6.7) 
Anti-diabetics 12 (5.0) 0 (0.0) 12 (4.0) 
Gynecological drugs 7 (2.9) 5 (4.0) 12 (4.0) 
Antihypertensive/ 10 (41.0) 0 (0.0) 10 (3.3) 
GIT (Spasmodic and Antispasmodics) 8 (3.3) 8 (13.8) 16 (5.3) 
Antihistamine 9 (4.7) 2 (3.2) 11 (3.7) 
Anti ulcer 9 (3.7) 1 (1.7) 10 (3.3) 
Anthelmintics 8 (3.3) 1 (1.3) 9 (3.0) 
Anti-tussive/expectorant 6 (2.5) 0 (0.0) 6 (2.0) 
Anti-asthmatics 6 (2.5) 0 (0.0) 6 (2.0) 
C.N.S active drugs 6 (2.5) 0 (0.0) 6 (2.0) 
Anticancer 2 (0.8) 0 (0.0) 2 (0.7) 




The result of this study revealed that most of the 
leaflets were directed to the consumers while the 
brochures were mainly physician-targeted.  Our 
study also revealed that none of the promotional 
materials had all the necessary information as 
stipulated by WHO’s Ethical Criteria for Medicinal 
Drug Promotion [1]. Quite a lot of studies have 
shown that many printed advertisements and 
drug promotional materials do not meet 
regulations and guidelines in force in various 
countries especially in developing countries. A 
study from Brazil noted that approximately 75 % 
of the advertisements did not comply with 
regulations in Brazil [5]. Similarly in a study 
carried out in Nepal [6], none of the promotional 
materials had all the necessary information when 
compared with WHO’s Ethical Criteria for 
Medicinal Drug Promotion [3]. Similarly, 
consumers’ reports in the U.S.A have shown that 
prescription drug information directed to patient 
and physicians were of little educational value 
[7]. Most marketing communication effort by 
pharmaceutical manufacturers concentrates on 
direct-to-patient-advertisement (DTPA) via drug 
promotional brochures and pharmaceutical sales 
representatives. The pharmaceutical industry 
invests large sums of money every year aimed at 
influencing the prescribing habits of physicians 
because, to a large degree, physicians regulate 
the amount of drugs bought by the consumers. 
Meanwhile, consumers seem not to constitute 
any major concern to the pharmaceutical 
industries as the direct-to-consumer information 
were rather superficial and none educational [7]. 
The results of this study is in congruence with 
work carried out in Pakistan where promotional 
materials were adjudged to be misleading, 
unjustifiable, exaggerated, ambiguous, false, and 
controversial [8]. 
 
Drug package leaflets, promotional materials 
and consumer education 
 
The increase in direct-to-consumer advertizing 
(DTCA) was driven in part by manufacturers’ 
need to be more aggressive at marketing their 
products and by regulators’ willingness to provide 
consumers with new information in the hopes of 
providing further education [9]. Ultimately, the 
argument that DTCA promotions educate the 
public about medical conditions and their 
treatments hinges on the quality of drug 
information available to consumers through 
advertising. However, our analyses found that 
educational quality is highly variable among the 
leaflets. None of them contained any information 
about the symptoms of the condition and 
clarifications about the condition-related 
misconception. Inclusion of the date of revision of 
the materials was 9.1 % in the leaflets. Despite 
the fact that health lifestyle and supportive 
behavior are important at all stages of the 
disease process, only 4.1 % described some of 
these changes in lifestyle that should be 
considered by patients using such medications. 
Healthy lifestyle and supportive behavior of the 
patient are important at all stages of the disease 
process and management but this information 
was lacking in most of the leaflets. Contrary to 
claims that promotional materials serve an 
educational purpose, our analysis show that the 
promotional material sampled provide limited 
information about the causes of diseases or who 
may be at risk. Some of them portray patients as 
people, who without the medications have lost 
control over their social, emotional or physical 
lives. A study has reported that some 
promotional materials have limited educational 
value and may oversell the benefits of drugs in 
ways that might conflict with promoting 
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population health [10]. In this study none of the 
materials listed behavioral changes that can 
improve the patient health either independently 
or in concert with the drug treatment. Behavioral 
recommendations such as diet, exercise, sleep 
pattern weight loss or smoking cessation are 
equally well known and are issues that must also 
be understood and addressed to ensure that the 
patient have every chance of achieving optimum 
health gain from any disease management 
strategy [11]. Negligence of behavioral changes 
that could significantly contribute to health of the 
patients seems to be a common defect of 
marketing promotional materials everywhere. 
 
Health literacy is defined as ‘‘the degree to which 
individuals have the capacity to obtain, process, 
and understand basic health information and 
services needed to make appropriate health 
decisions”. Hence the consumer must 
understand the language in which the information 
on health is being presented. One strategy of 
making medicine information more readable and 
useful is by providing them in consumer’s 
primary language [12]. English language is not 
the native language of Nigeria but this study 
revealed that none of the promotional materials 
was produced in the user’s primary language 
(Igbo, Hausa or Yoruba). Most of the bilingual 
leaflets are in English and French, and only few 
Nigerians can read French. This can affect 
readability as a number of consumers can only 
read and understand their primary language. For 
a material to be considered educative, accurate 
and non-misleading, the language should be 
comprehensible to the consumers.  
 
Limitations of the study 
 
Our study was subject to the following limitations, 
and the results were interpreted in this light: The 
study included only the leaflets and promotional 
materials which were available and accessible to 
the researchers during the period of the study, it 
remains possible that inclusion of these available 
materials in the study may have differed in some 
important way from those which were not 
included. Reviewers’ (two independent panels) 
bias was a potential limitation due to differences 
in reviewers’ attitude, though we believe that this 
effect should be minimal as there was a 
guideline/template for guided judgment and 





This study reveals that advertising materials 
used in promoting drugs in Nigeria have 
incomplete information and the physical 
characteristics of the materials are not adequate. 
Information in some pharmaceutical brochures 
exaggerated the benefits of the drug and 
downplayed risks associated with the drugs. This 
issue is of major concern because in a country 
like Nigeria, drug promotional materials are 
considered one of the major sources of drug 
information. Therefore, there is urgent need for 
the Pharmaceutical advertisements to be 
subjected to more strict regulations before being 
published. Health care providers should be 
cautious about the reliability of information in all 
drug leaflets and promotional materials and 
should follow principles of evidence based 
medicine in assessing the validity of information 
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